Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

HTTPS

Secure .gov websites use HTTPS
A lock ( Lock A locked padlock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

  • Environmental Topics
  • Laws & Regulations
  • Report a Violation
  • About EPA
Risk Assessment
Contact Us

Evaluating Antigen-Specific IgE Using The Rat Basophill Leukemia Cell (RBL) Assay

On this page:

  • Overview
  • Downloads
Allergic diseases (atopy) include asthma, allergic rhinitis, conjunctivitis, and allergic sinusitis. It is estimated that up to 90% of asthmatics are atopic and have an allergy trigger for asthmatic episodes. In order to assess the risk of allergy induction associated with inhalation exposure, animal models of protein allergy have been developed. These models have been used both to identify proteins as allergens and to assess their relative potency. Often these research situations include allergens that are not well characterized or are unknown. In these situations, specific allergens are not available to be evaluated by more well-known assays (such as ELISAs), and developing a specific assay to evaluate an extract or mixture for an unknown or potential allergen is very time consuming and generally requires purified antigen/allergen. Additionally, when the comparison of the relative potency of multiple extracts is of interest, a common/generic platform is necessary. A more generic method, the rat basophil leukemia cell assay (RBL assay), has been developed which provides insight into the allergenicity of extracts and mixtures as well as providing a common platform for relative potency comparison between/among these complex allergen sources.    

Impact/Purpose

The immune system functions to establish and maintain homeostasis by distinguishing endogenous ("self'") from exogenous components ("non-self"), thus protecting the body from infectious agents (bacteria, viruses, fungi, parasites) and certain tumors. Perturbation of this affinity and avidity to the individual antigens. Therefore an assay system that provides a common/generic platform is necessary.

Citation

Ward, M. AND L. Copeland. Evaluating Antigen-Specific IgE Using The Rat Basophill Leukemia Cell (RBL) Assay. Chapter 187, J. DeWitt, C. Rockwell, C. Bowman Immunotoxicity Testing. Humana Press Incorporated, Totowa, NJ, 1803(187):371-381, (2018). [DOI: 10.1007/978-1-4939-8549-4_22]

Download(s)

DOI: Evaluating Antigen-Specific IgE Using The Rat Basophill Leukemia Cell (RBL) Assay
  • Risk Assessment Home
  • About Risk Assessment
  • Risk Recent Additions
  • Human Health Risk Assessment
  • Ecological Risk Assessment
  • Risk Advanced Search
    • Risk Publications
  • Risk Assessment Guidance
  • Risk Tools and Databases
  • Superfund Risk Assessment
  • Where you live
Contact Us to ask a question, provide feedback, or report a problem.
Last updated on May 19, 2021
United States Environmental Protection Agency

Discover.

  • Accessibility Statement
  • Budget & Performance
  • Contracting
  • EPA www Web Snapshots
  • Grants
  • No FEAR Act Data
  • Privacy
  • Privacy and Security Notice

Connect.

  • Data
  • Inspector General
  • Jobs
  • Newsroom
  • Open Government
  • Regulations.gov
  • Subscribe
  • USA.gov
  • White House

Ask.

  • Contact EPA
  • EPA Disclaimers
  • Hotlines
  • FOIA Requests
  • Frequent Questions

Follow.